Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy

Minjee Kim, Janice K. Laramy, Gautham Gampa, Karen E. Parrish, Richard Brundage, Jann N. Sarkaria, and William F. Elmquist

Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (M.K., J.K.L., G.G., K.E.P., W.F.E.); Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota (R.B.); and Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.)

Received July 12, 2019; accepted October 1, 2019

ABSTRACT

Achieving an effective drug concentration in the brain is as important as targeting the right pathway when developing targeted agents for brain tumors. SAR405838 is a novel molecularly targeted agent that is in clinical trials for various solid tumors. Its application for tumors in the brain has not yet been examined, even though the target, the MDM2-p53 interaction, is attractive for tumors that could occur in the brain, including glioblastoma and brain metastases. In vitro and in vivo studies indicate that SAR405838 is a substrate of P-glycoprotein (P-gp). P-gp mediated active efflux at the blood-brain barrier plays a dominant role in limiting SAR405838 brain distribution. Even though the absence of P-gp significantly increases the drug exposure in the brain, the systemic exposure, including absorption and clearance processes, were unaffected by P-gp deletion. Model-based parameters of SAR405838 distribution across the blood-brain barrier indicate the Cl_{brain} of the brain was approximately 40-fold greater than the Cl_{in}. The free fraction of SAR405838 in plasma and brain were found to be low, and subsequent K_{pu} values were less than unity, even in P-gp/Bcrp knockout mice. These results indicate additional efflux transporters other than P-gp and Bcrp may be limiting distribution of SAR405838 to the brain. Concomitant administration of elacridar significantly increased brain exposure, also without affecting the systemic exposure. This study characterized the brain distributional kinetics of SAR405838, a novel MDM2 inhibitor, to evaluate its potential in the treatment of primary and metastatic brain tumors.

SIGNIFICANCE STATEMENT

This paper examined the brain distributional kinetics of a novel MDM2-p53 targeted agent, SAR405838, to see its possible application for brain tumors by using in vitro, in vivo, and in silico approaches. SAR405838 is found to be a substrate of P-glycoprotein (P-gp), which limits its distribution to the brain. Based on the findings in the paper, manipulation of the function of P-gp can significantly increase the brain exposure of SAR405838, which may give an insight on its potential benefit as a treatment for primary and metastatic brain cancer.

Introduction

The tumor suppressor p53 has been an attractive target in cancer therapeutics due to its crucial role in tumorigenesis (Hainaut and Hollstein, 2000; Vogelstein et al., 2000). The signaling pathway of p53 is found to be inactivated in various types of human cancers, often without a gene mutation in p53 itself (Wade et al., 2013). Therefore, it was a challenge to find ways to reactivate this protein in tumor cells for therapeutic purposes, until the role of the oncoprotein murine double minute 2 (MDM2) was discovered (Momand et al., 1992; Finlay, 1993). MDM2 has been identified as a major negative regulator of p53 by either direct binding or ubiquitination, leading to degradation (Momand et al., 2000; Wade et al., 2013). MDM2 is often amplified or overexpressed in various tumors, which leads to cancer development by downregulating p53 (Wade et al., 2013). Therefore, reactivation of p53 in tumors by the use of small molecule antagonists that target the interaction between MDM2 and p53 has been investigated as a novel molecularly targeted therapy for various cancers.

Currently there are several small molecule MDM2 antagonists under clinical investigation for various solid tumors. One of these, SAR405838 (Fig. 1), is a potent inhibitor that has high selectivity and affinity to MDM2 (K_{i} = 0.88 nM) (Wang et al., 2014). A previous study from our group has shown that SAR405838 was highly efficacious in a patient-derived xenograft model of glioblastoma (GBM) both in vitro and in heterotopic tumor implanted subcutaneously in the flank (Kim et al., 2018b). However, SAR405838 showed a lack of efficacy against an orthotopic tumor model, where the tumor was implanted intracerebrally. We conclude that this is likely due to limited delivery of SAR405838 to the tumor in the brain (Kim et al., 2018b). Interestingly, the in vivo orthotopic efficacy of SAR405838 was shown to be significantly greater than the orthotopic efficacy in the tumor in the flank.

This work was supported by the National Institutes of Health [Grants R01 CA138437, R01 NS077921, U54 CA210181, U01 CA227954, and P50 CA108960].

https://doi.org/10.1124/dmd.119.088716.

ABBRVIATIONS: AUC, area under the curve; BBB, blood-brain barrier; BCRP, breast cancer resistance protein; CL, clearance; CNS, central nervous system; DA, distribution advantage; fu, free (unbound) fraction; FVB, Friend leukemia virus strain B; GBM, glioblastoma; K_{el}, elimination rate constant; Kp, brain-to-plasma ratio; K_{pu}, brain unbound (free) brain-to-plasma ratio; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MDCKII, Madin-Darby canine kidney II; MDM2, mouse double minute 2 homolog; Mdr1, multi-drug resistance protein 1 (p-glycoprotein); MTT, mean transit time; NCA, noncompartmental analysis; N.S., not significant; P-gp, P-glycoprotein; p53, tumor protein p53; PKO, Mdr1a/b^{-/-}; RED, rapid equilibrium dialysis; TKO, triple knockout; WT, wild type.
increased in a tumor line where the BBB was disrupted by the overexpression of vascular endothelial growth factor A (Kim et al., 2018b). These data indicate that the brain distribution of this MDM2 inhibitor is a crucial factor in limiting treatment efficacy for infiltrative brain tumors, such as GBM (Sarkaria et al., 2018). Therefore, it is critical to understand the mechanisms that limit SAR405838 entry into the brain at an intact BBB. Clearly, adequate SAR405838 exposure in the brain depends on both systemic pharmacokinetic properties and distribution across the BBB, exemplified by SAR405838 efficacy in the patient-derived xenograft model of GBM dependence on the brain delivery of the compound (Kim et al., 2018b).

Brain distribution of many agents is often limited by the blood-brain barrier (BBB), which is characterized by tight and adherens junctions, that blocks the intercellular pathway for small molecules and by expression of efflux transporters that limit transcellular transport. Many of the molecularly targeted anti-cancer therapeutics are not able to penetrate the BBB and are subject to these active efflux transporters, including P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp). P-gp and Bcrp are highly expressed active efflux transporters at the BBB of the mouse (Agarwal et al., 2012) and human (Uchida et al., 2011). How these transporters influence the brain delivery of SAR405838 is critical in understanding the delivery and efficacy in the context of tumors in the brain, whether they be primary tumors, such as GBM (Cancer Genome Atlas Research Network, 2008), or metastatic brain tumors that may overexpress MDM2 and have areas with an intact BBB (Wade et al., 2013).

The objective of the current study was to examine the role of major efflux transporters, P-gp and Bcrp, on the brain distribution of SAR405838 using in vitro and in vivo methods. Moreover, a compartmental model was developed for quantitative and mechanistic understanding of the distributional kinetics of SAR405838 into and out of the brain tumors at the BBB. These studies provide insights on the use of SAR405838 in brain tumor therapy.

Materials and Methods

Chemicals and Reagents

(2S,3S,4S,5S)-3-chloro-1,2-dihydro-1,1a,6,10b-tetrahydrodibenzo-(a,e)cycloheptalyn-1-yl)-1-piperazine ethanol, trihydrochloride (zosuquidar) was kindly provided Eli Lilly and Co. (Indianapolis, IN). All other chemicals and reagents used were high-performance liquid chromatography grade from Thermo Fisher Scientific. The rapid equilibrium dialysis (RED) base plate and membrane inserts (8 kDa molecular weight cut-off cellulose membrane) were purchased from Thermo Fisher Scientific.

Animals

An equal number of female and male Friend Leukemia Virus strain B (FVB) wild-type and transgenic mice lacking either or both efflux transporters, Mdr1a or Mdr1b including Bcrp1(−/−), Mdr1aMdr1b−/−, and Mdr1aMdr1bBcrp1(−/−) mice (Taconic Biosciences, Inc., Germantown, NY) at the age of 8–14 weeks were used for the experiments. Animal colonies were maintained and housed in Research Animal Resources (RAR) facility located at the Academic Health Center, University of Minnesota, following an established breeding protocol. Animal genotypes were routinely verified by conducting tail snip (TransnetYX, Cordova, TN). All protocols for the animal experiments were approved by University of Minnesota Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals established by the U.S. National Institutes of Health (Bethesda, MD).

In Vitro Cell Accumulation

Cell accumulation experiments were performed with Madin-Darby canine kidney II (MDCKII) cells that overexpress either human multidrug resistance protein 1 (P-glycoprotein, MDR1) or murine breast cancer resistance protein (Bcrp1) or vector-controlled cells. Bcrp1 transfected (MDCKII-BCRP) and P-gp transfected (MDCKII-MDR1) cell lines were kindly provided by Dr. Alfred Schinkel and Dr. Piet Borst (The Netherlands Cancer Institute), respectively. Cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) fetal bovine serum and antibiotics (penicillin, 100 U/ml; streptomycin, 100 mg/ml; amphotericin B, 250 mg/ml). Cells were seeded in 12-well polystyrene plates with a density of 4 × 104 cells/well 1 day prior to the experiment (over 80% confluent). Cells were washed with serum free cell assay buffer containing 10 mM HEPES and then preincubated with either buffer alone or with a selective inhibitor for P-gp (1 μM of LY335979) or Bcrp1 (0.2 μM of Ko-143) for 30 minutes. Cells were incubated with 2 μM of SAR405838 with or without the selective transporter inhibitor for 60 minutes at 37°C with 60 rpm of agitation in an orbital shaker. At the end of incubation, cells were washed with ice-cold PBS twice to quench transport prior to cell lysis with 1% Triton X-100. The activities of efflux transporters expressed in the cell were validated using positive controls, [3H]vinblastine for P-gp and [3H]prazosin for Bcrp. The lysates were stored in −80°C freezer until the analysis with liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), and intracellular concentration was normalized to the cellular protein content measured by the BCA assay.

Free Fraction in Mouse Plasma and Brain Homogenate

The free fractions of SAR405838 in mouse plasma and brain homogenate were determined by using a rapid equilibrium dialysis (RED) device according to the manufacturer’s protocol. Briefly, the brain homogenate was prepared by adding two volumes (v/v) of PBS (pH 7.4) followed by mechanical homogenization. SAR405838 was added to mouse plasma or brain homogenate to a final concentration of 5 μM containing 0.3% DMSO. The matrix with the drug was loaded into the sample chamber (300 μl) of the inserts first, and then 500 μl of blank PBS was added into the corresponding buffer chamber. The base plate was sealed with an adhesive lid and incubated at 37°C for 4 hours in an orbital shaker with a 300 rpm of agitation. At the end of incubation, samples were collected from both chambers and stored in −80°C freezer until LC-MS/MS analysis. Undiluted free fraction in the brain was calculated with the equation below reported previously (Kalvass and Maurer, 2002):

\[
\text{Free fraction}(fu) = \frac{1}{D} \left( \frac{1}{\text{fraction of tissue}} - 1 \right) + \frac{1}{D}
\]

(1)
The dilution factor (D) was 3 in the experiment described above. The unbound (free) concentration partitioning to the brain was determined as shown below:

$$K_{p, brain} = \frac{\text{free brain concentration}}{\text{free plasma concentration}}$$

where $K_{p, brain}$ is the ratio of brain-to-plasma areas under the total concentration time profile.

### Systemic and Distributional Pharmacokinetics

**Concentration-Time Profile after a Single Oral or Intravenous Administration of SAR405838**

A single dose of SAR405838 was administered by oral gavage (25 mg/kg) or tail vein injection (5 mg/kg) in a solution to wild-type and genetic knockout FVB mice. The dosing solution was prepared with 98% of PEG2000 (v/v) and 2% of TPGS (v/v) for the oral administration or 10% of PEG4000 (v/v), 3% of Cremophor (v/v), and 87% of PBS (v/v) for the intravenous study. Blood and brain samples were collected at the predetermined time points ranging from 0.5 to 24 hours after oral administration or from 0.167 to 10 hours after intravenous administration ($\eta = 4$ at each time point). Mouse whole blood was collected via cardiac puncture using heparinized syringes after mice were euthanized in a carbon dioxide chamber. Plasma was separated by centrifugation at 3500 rpm at 4°C for 20 minutes. Plasma and brain samples were stored at −80°C until LC-MS/MS analysis.

### Pharmacological Inhibition of Efflux Transporters

Elacridar (a dual inhibitor of P-glycoprotein and Bcrp) and LY335979 (zosuquidar, a selective P-gp inhibitor) were prepared in a microemulsion formulation as described previously (Sane et al., 2013). Both inhibitors formulated in the microemulsion were diluted with two volumes of sterile water to a final concentration of 1 mg/ml. Vehicle control was formulated in the same manner, including all components of the microemulsion, but without any inhibitor. Wild-type FVB mice received either vehicle control or 5 mg/kg of inhibitor, either elacridar or LY335979 (zosuquidar) by tail vein injection. A dose of 25 mg/kg of SAR405838 was administered orally 1 hour after the administration of either vehicle control or inhibitors. Blood and brain samples were collected as described in pharmacokinetic experiment, 2 hours following the administration of SAR405838, and stored at −80°C until LC-MS/MS analysis.

### LC-MS/MS Bioanalysis

An LC-MS/MS method was developed by using reverse-phase liquid chromatography (Waters AQUITY ultra performance liquid chromatography system; Waters, Milford, MA) interfaced with a Waters Micromass Quattro LC-MS/MS Bioanalysis system; Waters, Milford, MA) interfaced with a Waters Micromass Quattro system; Waters, Milford, MA) interfaced with a Waters Micromass Quattro system interfaced with the Waters AQUITY ultra performance liquid chromatography system. Mobile phase was composed of aqueous phase (A) of 55% distilled and filtered water with 0.1% formic acid and organic phase (B) of 45% acetonitrile with 0.1% formic acid in negative ion mode. Chromatographic separation was performed by injecting 10 µl of reconstituted sample onto an ZORBAX Eclipse XDB-C18 column (Rapid Resolution HT 4.6 × 50 mm 1.8 µm; Agilent, Santa Clara, CA). Mobile phase was composed of aqueous phase (A) of 55% distilled and filtered water with 0.1% formic acid and organic phase (B) of 45% acetonitrile with 0.1% formic acid using an isocratic method. The total assay run time was 8 minutes, while the retention time for SAR405838 and internal standard (PLX-4720) were 1.95 and 5.45 minutes, respectively. SAR405838 and internal standard were detected with the mass transition of 560 > 305.9 and 411.9 > 304.86, respectively. These methods were sensitive and linear over the range of 1–5000 ng/ml with coefficient of variation of less than 15% (weighting factor of 1/Y²). All the specimen concentrations measured were within the range of calibration curve.

### Pharmacokinetic Data Analysis

**Non-Compartmental Analysis**

Concentration-time profiles in plasma and brain after a single oral or intravenous dose of SAR405838 were analyzed by using Phoenix WinNonlin version 6.4 (Certara USA Inc., Princeton, NJ). Pharmacokinetic parameters and metrics were calculated by non-compartmental analysis (NCA). Areas under the curve (AUCs) from time 0 to infinity for plasma and brain were calculated by log-linear trapezoidal integration, and the extrapolation for AUC from last time point to infinite time was calculated by dividing the last concentration measured by the terminal elimination rate constant, determined from the last three to four points in the concentration-time profiles. Other pharmacokinetic parameters, including systemic clearance (CL), volume of distribution, and $\tau_{1/2}$ (half-life), were calculated by using NCA. The brain concentrations were not corrected by residual blood volume of microvasculature in the brain, because the correction resulted in negative concentration in the brain of wild-type and Bcrp⁻/⁻ mice (Fridén et al., 2010).

The brain-to-plasma partition coefficient ($K_{p, brain}$) was calculated as below:

$$K_{p, brain} = \frac{AUC_{brain}}{AUC_{plasma}}$$

where $K_{p, brain}$ is an area under the curve from time zero to infinity of brain concentration-time profile ([$AUC_{0→∞, brain}$]) and $AUC_{plasma}$ is an area under the curve plasma concentration-time profile ([$AUC_{0→∞, plasma}$]).

The brain partition coefficient of free drug was calculated as described above in methods for free fraction. The distribution advantage (DA) to the brain resulting from lack of P-gp- and/or Bcrp-mediated efflux at the BBB was determined by the ratio of $K_{p, brain}$ to $K_{p, brain}$ to understand the magnitude of the role efflux transporters play in the brain distribution of SAR405838. The oral bioavailability of SAR405838 was calculated by the following equation:

$$\text{Oral bioavailability}(F) = \frac{AUC_{0→∞, plasma\;\text{oral}}}{AUC_{0→∞, plasma\;\text{iv}}} \times \text{Dose}_{oral} / \text{Dose}_{iv}$$

Where the $AUC_{0→∞, plasma\;\text{oral}}$ is the area under the curve from time zero to infinity of plasma concentration-time profile following a single oral dose and $AUC_{0→∞, plasma\;\text{iv}}$ is the area under the curve from time zero to infinity of plasma concentration-time profile following a single intravenous dose.

**Compartmental Analysis with a BBB Model**

A compartmental model that includes a brain compartment (BBB model) was used to quantitatively assess the rate and extent of SAR405838 distribution into and out of the mouse brain (Liu et al., 2005; Larany et al., 2018). The model was fit to the data in two steps. First, a one-compartment model was fit to wild-type (WT) and triple knockout (TKO) mean pooled plasma concentration-time data from a single intravenous bolus (Fig. 2A), given that there was no difference between WT and TKO plasma concentration profiles and individual model fit yielded the same disposition parameters for each genotype. These systemic disposition parameters, i.e., clearance (CL), the volume of distribution (Vc), and elimination rate constant from the central compartment (Kε) for wild-type and triple-knockout FVB mice were determined using the one-compartment model fit to the data obtained following a single intravenous administration. Then, absorption rate constants for each genotype were estimated from the model fitted to the observed plasma data following a single oral administration. In the second step, a compartmental model that includes a brain compartment was fit to the observed brain concentration-time profile data either from an intravenous bolus or an oral administration (Fig. 2B). A forcing function, comprised of the systemic disposition parameters obtained in step 1, including the absorption rate constant when appropriate, was implemented to describe the plasma concentration in the central compartment and used as an input function into the compartmental BBB model. Simulation and model fitting for systemic disposition and brain distribution were performed by using SAAM II (version 2.3; The Epsilon Group, Charlottesville, VA).

The changes in total brain concentration with respect to time were described by using the following differential equation:

$$V_{brain} \times \frac{dC_{brain}}{dt} = K_{in} \times (V_c \times C_{plasma}) - K_{out} \times (V_{brain} \times C_{brain})$$

where $V_{brain}$ is the apparent volume of distribution in the brain, $K_{in}$ and $K_{out}$ are the first-order rate constants that describe the rates into and out of the brain, and $V_c$ is the volume of distribution of total drug in the central compartment. In this model, $C_{plasma}$ is the predicted total drug concentration in plasma under the model from step 1, and $C_{brain}$ is the observed total drug concentrations in brain. Given that the total concentration of drug was measured in the brain as the reference concentration to relate to the total amount in brain, the $V_{brain}$ for SAR405838 was estimated to be the same as the anatomic volume of mouse brain that was...
obtained from the overall average of our in vivo experiments, i.e., 0.42 ± 0.034 ml/g brain. The clearances into and out of the brain were calculated with the model estimated $K_{in}$ and $K_{out}$ of the brain by using following equations:

$$C_{in} = K_{in} \times V_c$$  \hspace{1cm} (6)
$$C_{out} = K_{out} \times V_{brain}.$$  \hspace{1cm} (7)

The exposure of brain tissue to SAR405838 was also quantified by the mean transit time (MTT) using the following equation (Kong and Jusko, 1988):

$$\text{Mean transit time in the brain}(MTT_{\text{brain}}) = \frac{1}{K_{\text{out}}} \hspace{1cm} (8)$$

Statistical Analysis

All data are presented as means ± S.D. or means ± S.E. of the estimate (S.E.). Comparison between two groups was tested by using an unpaired two-sample t test with GraphPad Prism version 6.04 (GraphPad, La Jolla, CA) software. A significance level of $P < 0.05$ was used for the test.

Results

In Vitro Cell Accumulation Assay. The role of the two efflux transporters that are highly expressed on the luminal membrane in the endothelial cell of brain microvasculature, P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (Bcrp, ABCG2), on the brain distribution of SAR405838 was initially examined using an in vitro cell accumulation assay in MDCKII wild-type, MDCKII-MDR1-overexpressing, and MDCKII-BCRP1-overexpressing cell lines. [3H]-Vinblastine and [3H]-prazosin were used as positive controls to check the functionality of P-gp and Bcrp, respectively, in the transfected cell lines. The intracellular accumulation of these positive control substrates was significantly lower in transporter-overexpressing cells compared with their normalized vector-controlled wild-type cells (Fig. 3) [wild-type (MDR1-vector control): 100% ± 32.18%, Mdr1: 36.7% ± 12.26%, $P < 0.05$; wild-type (BCRP-vector control): 100% ± 11.0%, Bcrp1: 29.83% ± 9.91%, $P < 0.01$]. When LY335979, a selective inhibitor of P-gp, and Ko-143, a selective inhibitor of Bcrp, were coincubated with their respective substrates, the intracellular accumulation was similar to the vector control due to inhibition of the respective efflux transporter (Fig. 3) [wild-type (MDR1) + LY335979: 130% ± 12.2%, MDR1 + LY335979: 158.3% ± 21.81%, (N.S.); wild-type (BCRP1) + Ko-143: 103.1% ± 13.7%, BCRP1 + Ko-143: 90.8% ± 19.9%, (N.S.)]. The accumulation of SAR405838 in MDCKII-MDR1 cells was only 35.2% of the corresponding vector-controlled cells, and this difference was abolished in the presence of the P-gp selective inhibitor, LY335979 (Fig. 3A) [139.8% ± 22.4%, $P < 0.0001$]. However, no significant difference was observed in the accumulation of SAR405838 between Bcrp vector control and Bcrp overexpressing cells (Fig. 3B) [Bcrp1: 121.5% ± 26.6%, (N.S.)]. These in vitro results indicate that SAR405838 is a substrate of P-gp, but not of Bcrp, suggesting that P-gp may play a significant role in limiting the brain distribution of SAR405838. The use of a selective and potent P-gp inhibitor, such as LY335979, was able to significantly diminish the function of P-gp, and increase the intracellular accumulation of SAR405838 in these in vitro experiments.

SAR405838 Disposition following Intravenous Dose. The brain and plasma concentration-time profiles were examined at multiple time points up to 10 hours after a single intravenous administration of SAR405838 in wild-type (WT) and triple knockout FVB mice (Mdr1a/1b−/−Bcrp1−/−) that lack both Mdr1a/b and Bcrp (Fig. 4, A and B). Concentrations of SAR405838 in plasma and brain were measured in the specimens that were collected at the predetermined time points after administration of 5 mg/kg SAR405838 by tail vein injection. The plasma concentrations over time [AUC(0−t) of SAR405838 in Mdr1a/1b−/−Bcrp1−/− mice were not significantly different than in wild-type FVB mice (Table 1, plasma AUC WT = 15,851 ± 542, plasma AUC Mdr1a/1b−/−Bcrp1−/− = 15,033 ± 761, N.S.). Importantly, this was not the case in the distribution of SAR405838 to the brain, where concentrations of SAR405838 in the brain were significantly higher in Mdr1a/1b−/−Bcrp1−/− mice compared with wild-type mice at all time points ($P < 0.05$). Both plasma and brain concentrations exhibit a monoe-exponential decline with respect to time for both wild-type and Mdr1a/1b−/−Bcrp1−/− mice. Brain-to-plasma ratios of SAR405838 were significantly higher in Mdr1a/1b−/−Bcrp1−/− than wild type and increased over time in the Mdr1a/1b−/−Bcrp1−/− genotype ($P < 0.05$) but did not increase after the second measurement (30 minutes) in the wild-type (N.S.) (Fig. 4C). Correspondingly, a plateau in the brain-to-plasma ratio was observed early post dose (30 minutes) in wild type, but it was not reached in Mdr1a/1b−/−Bcrp1−/− even after 10 hours after the dose. Plasma pharmacokinetic parameters and metrics were calculated in both wild type and Mdr1a/1b−/−Bcrp1−/− (Table 1). The wild type and Mdr1a/1b−/−Bcrp1−/− mice had a terminal elimination half-life of 2.25 and 2.76 hours, volume of distribution (Vd) of 973 and 1227 ml/kg and systemic clearance of 300 and 308 (ml/h)/kg, respectively, indicating that there are no differences in the systemic elimination of SAR405838 between these two transporter genotypes.
Also, the brain partition coefficient, calculated using $AUC_{\text{brain}} / AUC_{\text{plasma}}$, was over 45-fold higher in Mdr1a/b$^{-/-}$Bcrp1$^{-/-}$ than wild type [0.0275 in wild type and 1.29 in Mdr1a/b$^{-/-}$Bcrp1$^{-/-}$] (Table 1), indicating that P-gp (Mdr1) is critical in limiting the BBB permeability and brain distribution of SAR405838.

SAR405838 Absorption and Disposition following Single Oral Dose. The brain and plasma concentration-time profiles were determined after a single oral dose of SAR405838 (25 mg/kg) in four different genotypes of mice, including wild type, Bcrp1$^{-/-}$, and Mdr1a/b$^{-/-}$Bcrp1$^{-/-}$ (Fig. 5). The plasma concentration-time profiles of SAR405838 were very similar among the different genotypes (Fig. 5A), even though there was some variability in $AUC_{0-\infty}$ of SAR405838 in the plasma was extremely low (0.059% of dose) (Table 2). The plasma concentrations at much later times in Mdr1a/b$^{-/-}$ and Mdr1a/b$^{-/-}$Bcrp1$^{-/-}$ mice. The $K_p$ values calculated from the brain and plasma AUCs after oral administration were much greater in Mdr1a/b$^{-/-}$ and Mdr1a/b$^{-/-}$Bcrp1$^{-/-}$ mice (2.35 and 1.53, respectively) than in wild type and Bcrp1$^{-/-}$ (0.0218 and 0.0285, respectively), suggesting the dominant influence of P-gp on the brain exposure of SAR405838. The corresponding brain distribution advantage achieved by eliminating the efflux mechanism was calculated in Bcrp1$^{-/-}$, Mdr1a/b$^{-/-}$, and Mdr1a/b$^{-/-}$Bcrp1$^{-/-}$ mice compared with wild-type mice and were 1.31, 108, and 70.1, respectively, after a single oral dose (Table 2).

The systemic oral bioavailability was calculated in both wild type and Mdr1a/b$^{-/-}$Bcrp1$^{-/-}$ and were 73.2% and 81%, respectively (Table 2). These similar values in bioavailability in these genotypes indicate that P-gp and Bcrp do not have a profound influence on the bioavailability of SAR405838, even though efflux transport significantly changes the brain exposure.

Plasma and Brain Unbound Fraction. The unbound fraction ($f_u$) of SAR405838 in plasma and brain homogenate was determined by using rapid equilibrium dialysis after a 4-hour incubation that was shown to be adequate time to reach equilibrium in pilot experiments. The $f_u$ of SAR405838 in the plasma was extremely low (0.059% ± 0.034%,
Brain-to-plasma ratio (Kpuu) values were calculated based on than that in the brain (0.015% brain-to-plasma ratio over time in wild-type, 3.8 times higher at 6 hours with elacridar (dual inhibitor), but there was no difference with LY335979 (selective P-gp inhibitor) (Fig. 6B).

**Brain Distributional Kinetics of SAR405838 Using BBB Modeling.** A one-compartment model was fit to mean pooled total plasma concentrations to describe the plasma concentration-time profile following a single intravenous administration and to yield systemic disposition parameters to use as a forcing function in the BBB model. The model predicted plasma concentration-time profiles, and the observed plasma concentrations from the experiments for intravenous administration are shown in Fig. 7. The systemic volume of distribution was estimated to be 1166 ml/kg, and the elimination rate constant (k_e) from the central compartment was estimated to be 0.269 hour^{-1} in Mdr1a/b^{−/−}Bcrp1^{−/−} animals. Initial models for both wild-type and triple-knockout animals were separately fit to the data obtained from each genotype and there were no differences in these systemic parameters between wild type and triple knockouts. Therefore, systemic parameters obtained from the mean pooled data were used for all genotypes and are summarized in Table 4. All parameter estimates were precisely estimated and had a coefficient of variation (CV) of less than 10%. With these parameter estimates, the systemic clearance of SAR405838 [314 (ml/h)/kg], half-life (t_{1/2}) (2.57 hours), and plasma concentration at time zero (C_{p0})...
that the tissue transfer rate constants into the brain (concentration-time profile in the central compartment for the compartment model were used in a forcing function to create a plasma concentration-time data after both intravenous bolus and oral administration, the volume of distribution for the central compartment to the total plasma concentration-time data of each genotype following administration, the volume of distribution for the central compartment was estimated to be 0.265 hour^{-1} (4288 ng/ml) were calculated (Table 4). These parameter estimates were then used in the plasma concentration-time forcing function to then estimate distribution parameters across the BBB.

One-compartment models for oral administration were individually fit to the total plasma concentration-time data of each genotype following an oral administration of SAR405838 to compare the absorption rate constants in wild-type and transgenic mice. For the models of oral administration, the volume of distribution for the central compartment and the systemic clearance from the central compartment were fixed as described in Table 5. The model predicted plasma concentration-time profiles for each genotype and the observed plasma concentration-time profiles are presented in Fig. 8. The absorption rate constants for each genotype were estimated to be 0.265 hour^{-1} in wild-type, 0.290 hour^{-1} in Bcrp1^{-/}, 0.240 hour^{-1} in Mdr1a/b^{-/}, and 0.258 hour^{-1} in Mdr1a/b^{-/} Mdr1a/b^{-/} mice (Table 5). All absorption rate constant parameter estimates had a coefficient of variation (CV) of less than 20%. Overall, the model predicted plasma concentration-time profiles for each genotype visually matched well with the observed plasma concentration-time data after both intravenous bolus and oral administration (Figs. 7 and 8).

As indicated above, to improve the estimation of the brain distribution parameters, estimated systemic disposition parameters from the one-compartment model were used in a forcing function to create a plasma concentration-time profile in the central compartment for the implementation of a BBB model. The model was fit to the concentration-time data by using eq. 5. The initial results using the BBB model confirmed that the tissue transfer rate constants into the brain (K_in) of each genotype are not different from one another. Therefore, given the initial results regarding K_in values, and to simplify the model by reducing the number of estimated parameters to improve precision, K_in values were fixed for all four genotypes using the value estimated in Mdr1a/b^{-/} Bcrp1^{-/} animals. The results from the BBB model were presented in Table 6. The tissue transfer rate constants into the brain (K_in) were estimated by the BBB model to be 1.12 × 10^{-4} hour^{-1} following intravenous bolus administration and 1.18 × 10^{-4} hour^{-1} following oral administration, and these values were not significantly different (P > 0.05). The estimated tissue transfer rate constants out of the brain (K_out) were much greater, ranging from 0.282 (PKO) to 0.300 (TKO) hour^{-1} in the P-gp deficient genotypes, and the transfer rate constants out of brain from wild-type and Bcrp knockout mice were 16.8 and 11.3 hour^{-1}, respectively, about 40-60 times higher than the P-gp deficient mice (Table 6). The resulting clearances into the brain (CL_in) were estimated by eq. 6 to be 0.131 (ml/h)/kg in intravenous study and 0.138 (ml/h)/kg in an oral dosing study. The resulting clearances out of the brain (CL_out), estimated using eq. 7, in p-gp deficient mice (PKO and TKO) were similar to the clearance into the brain, however, that in wild-type and Bcrp knockout mice were much higher than the clearance into the brain, as expected, mainly due to the efflux by P-gp (see Table 6).

The mean transit time in the brain (MTT) was calculated by eq. 8 to quantify the exposure time of brain to SAR405838. As expected, the brain exposure to SAR405838, as quantified by MTT was significantly longer in Mdr1a/b^{-/} and Mdr1a/b^{-/} Bcrp1^{-/} genotypes following both an intravenous bolus (2.32 hours in Mdr1a/b^{-/} Bcrp1^{-/}) and an oral bolus (1.92 hours in Mdr1a/b^{-/} Bcrp1^{-/}) and an oral bolus (1.92 hours in Mdr1a/b^{-/} Bcrp1^{-/}) and an oral bolus (1.92 hours in Mdr1a/b^{-/} Bcrp1^{-/}) and an oral bolus (1.92 hours in Mdr1a/b^{-/} Bcrp1^{-/}).

### Table 2: Pharmacokinetic/metric parameters determined by non-compartmental analysis following a single oral dose of SAR405838 (25 mg/kg) in wild-type, Mdr1a/b^{-/}, Bcrp1^{-/}, and Mdr1a/b^{-/} Bcrp1^{-/} FVB mice

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Wild Type</th>
<th>Mdr1a/b^{-/}</th>
<th>Bcrp1^{-/}</th>
<th>Mdr1a/b^{-/} Bcrp1^{-/}</th>
<th>Wild Type</th>
<th>Mdr1a/b^{-/}</th>
<th>Bcrp1^{-/}</th>
<th>Mdr1a/b^{-/} Bcrp1^{-/}</th>
</tr>
</thead>
<tbody>
<tr>
<td>t_{1/2}</td>
<td>3.26</td>
<td>4.18</td>
<td>3.02</td>
<td>5.08</td>
<td>4.03</td>
<td>10.1</td>
<td>3.36</td>
<td>12.1</td>
</tr>
<tr>
<td>T_{max}</td>
<td>8</td>
<td>8</td>
<td>4</td>
<td>2</td>
<td>8</td>
<td>16</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>C_{max} (ng/ml)</td>
<td>4651</td>
<td>3582</td>
<td>7299</td>
<td>6164</td>
<td>161</td>
<td>4176</td>
<td>159</td>
<td>4554</td>
</tr>
<tr>
<td>AUC_{0-τ} (h*ng/ml)</td>
<td>60,425 ± 3584</td>
<td>40,490 ± 2559</td>
<td>68,107 ± 1919</td>
<td>62,490 ± 7253</td>
<td>1995 ± 132</td>
<td>74,213 ± 5908</td>
<td>1925 ± 249</td>
<td>75,281 ± 9392</td>
</tr>
<tr>
<td>F oral</td>
<td>0.732</td>
<td>NA</td>
<td>NA</td>
<td>0.809</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Vd/F (ml/kg)</td>
<td>1922</td>
<td>3642</td>
<td>1585</td>
<td>2778</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>CL/F (ml/kg)</td>
<td>409</td>
<td>604</td>
<td>364</td>
<td>379</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>K_{Pbrain}</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0.0218</td>
<td>2.35</td>
<td>0.0285</td>
<td>1.53</td>
<td>—</td>
</tr>
<tr>
<td>DA</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>2.35</td>
<td>0.0285</td>
<td>1.53</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

### Table 3: Free fraction (fu) values, partition coefficient of brain (K_{Pbrain} and K_{P_{brain, brain}}), and distribution advantage

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Intravenous</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>K_{Pbrain}</td>
<td>0.0275</td>
<td>0.0218</td>
</tr>
<tr>
<td>f_{u, plasma}</td>
<td>0.00059 ± 0.00034</td>
<td>0.006</td>
</tr>
<tr>
<td>f_{u, brain}</td>
<td>0.00015 ± 0.000035</td>
<td>0.598</td>
</tr>
<tr>
<td>K_{P_{brain, brain}}</td>
<td>0.007</td>
<td>0.007</td>
</tr>
<tr>
<td>DA_{total}</td>
<td>1 46.8</td>
<td>108 1.31</td>
</tr>
</tbody>
</table>
administration (3.55 and 3.33 hours, respectively) than in wild type and Bcrp1−/− (0.082 hours after an intravenous bolus; 0.060 and 0.089 hours after an oral dose) as summarized in Tables 6 and 7. In conclusion, the total drug exposure time in the brain is significantly increased in the absence of P-gp (Mdr1), the efflux system that plays a leading role at the BBB in preventing SAR405838 access to the brain.

Based on the pharmacokinetic parameters and metrics estimated from the compartmental BBB model, the predicted partition coefficient of the brain, distribution advantage, and the ratio of clearance into the brain to clearance out of the brain were calculated and summarized in Table 7. The predicted partition coefficient of the brain and the ratio of clearances were closely matched with the observed $K_p$ values calculated with the results from NCA (Tables 1 and 2). The ratios of the clearance into and out of the brain were calculated and compared with $K_p$ values, and clearance ratios and predicted $K_p$ from the models closely matched with each other in all genotypes. The agreement of the model-based predicted values to the observed values support the assumptions in the compartmental models and the model described the data well.

**Discussion**

Challenges in the successful treatment of primary and metastatic brain tumors include insufficient and heterogeneous distribution of therapeutics across an intact BBB, which can lead to lack of efficacy, as well as acquired drug resistance due to exposure to subtherapeutic concentrations (Lockman et al., 2010; Pafundi et al., 2013). Therefore, it is important when examining innovative therapeutic agents that target novel signaling pathways in brain tumors to understand the pharmacokinetic properties and distributional kinetics of these agents to the brain. SAR405838 was recently developed to target the p53 and MDM2 interaction, and it has advanced to clinical testing for the treatment of various solid tumors (Wang et al., 2014), but its efficacy in brain tumors was only recently addressed (Kim et al., 2018b). Given the general mechanism of action of p53 enhancement and the fact that some glioblastoma and other tumors of the brain overexpress MDM2, there is
Brain Distributional Kinetics of SAR405838

In vitro cell accumulation experiments using MDCKII cells transfected with efflux transporter genes have confirmed that SAR405838 is a substrate of human P-gp, but it may not be a substrate of mouse Bcrp. LY335979 (zosuquidar), a selective competitive inhibitor of P-gp, increased the intracellular accumulation of SAR405838. Consistent with the in vitro study results, in vivo studies with wild-type and transporter knockout mice have confirmed that P-gp plays a crucial role in brain distribution of SAR405838. It is valuable to describe the distributional kinetics after an oral administration of SAR405838, because this drug is a substrate of human P-gp, but it may not be a substrate of mouse Bcrp. The in vivo study results, in vivo studies with wild-type and transporter knockout mice have confirmed that P-gp plays a crucial role in brain distribution of SAR405838. It is valuable to describe the distributional kinetics after an oral administration of SAR405838, because this drug is a substrate of human P-gp, but it may not be a substrate of mouse Bcrp.

Recent studies from our group examined the potential efficacy of SAR405838 in a patient-derived xenograft model of primary brain tumor, glioblastoma (GBM). The overall conclusion of that study was that the limited brain distribution of SAR405838 diminishes its value as an effective treatment of brain tumor (Kim et al., 2018b). However, the specific mechanisms that influence the adequate delivery of an active concentration of SAR405838 to the brain or brain tumor were not examined. The current study shows that, of the most highly expressed efflux transporters in the BBB, SAR405838 is a substrate of P-glycoprotein (P-gp). P-gp and Bcrp are highly expressed in brain endothelial cells of human and mouse (Uchida et al., 2011; Agarwal et al., 2012), therefore it can be expected that P-gp may limit the distribution, hence the efficacy of SAR405838 in both the preclinical and clinical settings of both primary (e.g., GBM) and secondary tumors in the CNS.

In vitro cell accumulation experiments using MDCKII cells transfected with efflux transporter genes have confirmed that SAR405838 is a substrate of human P-gp, but it may not be a substrate of mouse Bcrp. LY335979 (zosuquidar), a selective competitive inhibitor of P-gp, increased the intracellular accumulation of SAR405838. Consistent with the in vitro study results, in vivo studies with wild-type and transporter knockout mice have confirmed that P-gp plays a crucial role in brain distribution of SAR405838. It is valuable to describe the distributional kinetics after an oral administration of SAR405838, because this drug is a substrate of human P-gp, but it may not be a substrate of mouse Bcrp. LY335979 (zosuquidar), a selective competitive inhibitor of P-gp, increased the intracellular accumulation of SAR405838. Consistent with the in vitro study results, in vivo studies with wild-type and transporter knockout mice have confirmed that P-gp plays a crucial role in brain distribution of SAR405838. It is valuable to describe the distributional kinetics after an oral administration of SAR405838, because this drug is a substrate of human P-gp, but it may not be a substrate of mouse Bcrp. LY335979 (zosuquidar), a selective competitive inhibitor of P-gp, increased the intracellular accumulation of SAR405838. Consistent with the in vitro study results, in vivo studies with wild-type and transporter knockout mice have confirmed that P-gp plays a crucial role in brain distribution of SAR405838. It is valuable to describe the distributional kinetics after an oral administration of SAR405838, because this drug is a substrate of human P-gp, but it may not be a substrate of mouse Bcrp.
distributional kinetics by calculating mean transit times (MTTs) and mean residence times of SAR405838 in the brain for in wild-type and transgenic mice that can be translated into a therapeutic exposure time in the brain. The mean residence time in the brain compartment is defined as the average number of times drug molecules visit the brain compartment (N) multiplied by the average time the molecule spends in the brain on one visit, the mean transit time (MTT) (Kong and Jusko, 1988). N is determined by the ratio of $K_{\text{in}}$ and $K_{\text{e,o rC Lin}}$ to $CL_{\text{sys}}$, which are assumed to be the same across genotypes (Kong and Jusko, 1988). Therefore, the exposure of brain to drug, as exemplified by the mean residence time, will be much higher in the P-gp deficient genotypes than the P-gp intact genotypes.

Nonspecific drug binding to proteins in plasma and tissue is a critical factor to consider for CNS pharmacodynamics as well as distributional kinetics according to the "free drug hypothesis" (Trainor, 2007). This is especially true for the drugs targeting the CNS, where it is the unbound drug concentrations and unbound AUCs in the brain and plasma that indicate involvement of active efflux processes in CNS delivery of drugs (Kalvass and Maurer, 2002; Hammarlund-Udenaes et al., 2008). With the assumption that the free drug concentrations in the brain and in the plasma are in equilibrium, unbound (free) drug partition coefficient of brain ($K_{\text{puu, brain}}$) is an informative parameter indicating the contribution of active transport (either influx or efflux) or metabolism in CNS drug distribution (Hammarlund-Udenaes et al., 2008).

There are several ways to experimentally determine the unbound drug concentration in the brain. Recently, the brain homogenate method using rapid equilibrium dialysis (RED) has been suggested as a valid way of determining brain unbound concentration (Waters et al., 2008; Liu et al., 2009). Even though the use of unbound fraction from equilibrium dialysis needs to be carefully evaluated, especially for lipophilic drugs that tend to be highly bound, the RED method is generally accepted as an efficient and practical way to understand tissue binding characteristics (Waters et al., 2008). Therefore, RED was used with brain homogenate and plasma to determine unbound brain and plasma concentrations in the

---

TABLE 6

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Intravenous</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype</td>
<td>Wild Type</td>
<td>Bcrp1(−/−)</td>
</tr>
<tr>
<td>$K_{\text{in}}$ (h$^{-1}$)</td>
<td>Mean</td>
<td>1.12E−04</td>
</tr>
<tr>
<td>CV (%)</td>
<td></td>
<td>1.17</td>
</tr>
<tr>
<td>$K_{\text{out}}$ (h$^{-1}$)</td>
<td>Mean</td>
<td>12.3</td>
</tr>
<tr>
<td>CV (%)</td>
<td></td>
<td>16.5</td>
</tr>
<tr>
<td>$CL_{\text{in}}$ (ml/h per kilogram)</td>
<td>Mean</td>
<td>0.131</td>
</tr>
<tr>
<td>CV (%)</td>
<td></td>
<td>18.5</td>
</tr>
<tr>
<td>$CL_{\text{out}}$ (ml/h per kilogram)</td>
<td>Mean</td>
<td>5.1</td>
</tr>
<tr>
<td>CV (%)</td>
<td></td>
<td>17.5</td>
</tr>
<tr>
<td>MTT (h)</td>
<td>Mean</td>
<td>0.082</td>
</tr>
<tr>
<td>$CL_{\text{in}}/CL_{\text{out}}$</td>
<td></td>
<td>0.026</td>
</tr>
</tbody>
</table>

$CL_{\text{in}}$, total drug clearance into the brain; $CL_{\text{out}}$, total drug clearance out of the brain; $K_{\text{in}}$, tissue transfer rate constant into the brain; $K_{\text{out}}$, tissue transfer rate constant out of the brain; MTT, mean transit time in the brain; calculated by $1/K_{\text{out}}$.
The presence of active efflux transporter, and these values increased in
the brain has been shown to be
role in limiting the brain distribution of a novel MDM2 inhibitor,
efflux transporters at the blood-brain barrier (P-gp and Bcrp), plays a key
study (Fig. 3).

In vitro study with MDCKII cells transfected with human MDR1 in this
site of SAR405838 to P-gp is different from that of LY335979 in mice,
LY335979, so LY335979 may need higher dose to have the similar
discrepancies in the results between elacridar and LY335979 might be
the same dose (5 mg/kg) of inhibitors, given similar concentrations. The
LY335979 against P-gp are reported to be similar (Jabeen et al.,
P-gp inhibitor, with SAR405838 did not change the brain delivery of
Bcrp, with SAR405838 significantly improves the drug exposure in the
brain without increasing the plasma concentration. There have been
concerns about using transporter inhibitors with anticancer agents due
to possible toxicity related to increased drug systemic exposure, because of
drug-drug interactions at the level of the systemic clearance. However,
for drugs that do not rely on transporters for their systemic clearance,
such as SAR405838, combination therapy with efflux transporter
inhibitors may be considered as a potential therapeutic strategy to
overcome the BBB, especially with molecularly targeted agents in the
treatment of glioblastoma, where only limited therapeutic regimens are
available. The dosage and the interlaced schedule of dosing of the two
interacting compounds need to be carefully assessed when using such a
therapeutic drug-drug interaction strategy in clinical setting. Interest-
ingly, coadministration of LY335979 (zosuquidar), a selective
P-gp inhibitor, with SAR405838 did not change the brain delivery of
SAR405838 in mice. The inhibitory potencies of elacridar and
LY335979 against P-gp are reported to be similar (Jabeen et al.,
2012), so the similar in vivo inhibitory efficacy might be expected with
the same dose (5 mg/kg) of inhibitors, given similar concentrations. The
discrepancies in the results between elacridar and LY335979 might be
explained in several ways. One possibility is that the availability of
a drug at the site of action, BBB in this case, can be lower with
LY335979, so LY335979 may need higher dose to have the similar
efficacy as elacridar. Another interesting possibility is that the binding
site of SAR405838 to P-gp is different from that of LY335979 in mice,
since LY335979 has been shown to inhibit human P-gp potently in the
in vitro study with MDCKII cells transfected with human MDR1 in this
study (Fig. 3).

In conclusion, this study has showed that P-glycoprotein, of the major
efflux transporters at the blood-brain barrier (P-gp and Bcrp), plays a key
role in limiting the brain distribution of a novel MDM2 inhibitor,
SAR405838. The distribution to the brain has been shown to be
increased significantly in mice that are lacking P-glycoprotein compared
with mice that have an intact P-gp at the BBB. Lack of P-gp did not
influence the systemic disposition (clearance or volume of distribution)
of SAR405838. Both NCA and compartmental analysis resulted in
similar estimates of systemic pharmacokinetic parameters and metrics,
and the compartmental BBB model provided additional insights into the
rate and extent of the delivery of SAR405838 to the brain. The model-
estimated tissue transfer rates out of the brain were significantly higher
in the presence of P-gp than in the absence of P-gp, even though the tissue
transfer rates into the brain were unchanged among genotypes. Based on
our findings, it may still be of interest to examine the efficacy of brain
penetrant MDM2 inhibitors in the GBM patient, as long as the
limitations in delivery across an intact BBB can be overcome. Treat-
ments for CNS tumors need to be able to penetrate the intact BBB to
have maximal therapeutic efficacy especially for the treatment of
infiltrative CNS tumors, such as GBM (Agarwal et al., 2011b). Even
though targeting MDM2 is promising for the treatment of GBM (Wade
et al., 2013), the ability of therapeutic agents to reach adequate
congestion in CNS will limit the potential efficacy due to lack of
BBB permeability (Kim et al., 2018b). Moreover, subtherapeutic
concentrations in CNS due to heterogeneous BBB permeability may
result in acquired drug resistance (Sacher et al., 2014; Jung et al., 2016;
Kim et al., 2018a). Therefore, it is critical to understand the delivery of
these agents to the brain and to find either a novel MDM2 inhibitor,
which can penetrate the intact BBB, modify the structure of SAR405838
to avoid the active efflux by P-gp, or find an additional novel means to
improve the delivery of MDM2 inhibitors through the BBB.

Acknowledgments

The authors thank Jim Fisher, Clinical Pharmacology Analytical Laboratory,
University of Minnesota, for his support in the development of the LC-MS/MS
assays.

Authorship Contributions

Participated in research design: Kim, Sarkaria, Elmquist.
Conducted experiments: Kim, Laramy, Parrish, Brundage, Sarkaria,
Elmquist.
Performed data analysis: Kim, Laramy, Parrish, Brundage, Sarkaria,
Elmquist.
Wrote or contributed to the writing of the manuscript: Kim, Brundage,
Sarkaria, Elmquist.

References

Agarwal S, Hartz AM, Elmquist WF, and Bauer B (2011a) Breast cancer resistance protein and


Address correspondence to: William F. Elmqquist, Department of Pharmaceutics, University of Minnesota, 308 Harvard ST SE, Minneapolis MN 55455. E-mail: elmqu011@umn.edu